Payment overview · 2025
General Payments
$60.33
4 reported records · 4 companies
Healthcare provider profile · identity verified
Chris A Clark, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GARLAND, TX · NPI 1760457857
Verified facts
What the public records show
CMS Open Payments records show Chris A Clark, M.D. received $60.33 in general payments during 2025 across 4 reported records.
Abbott Laboratories accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.08 | 28.3% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $15.31 | 25.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.34 | 23.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.60 | 22.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $60.33 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 375 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 355 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 320 | 87 |
| Lisinopril | Lisinopril | 273 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 261 | 80 |
| Omeprazole | Omeprazole | 205 | 65 |
| Trazodone Hcl | Trazodone Hcl | 175 | 39 |
| Gabapentin | Gabapentin | 173 | 40 |
| Simvastatin | Simvastatin | 172 | 49 |
| Alprazolam | Alprazolam | 165 | 48 |
| Montelukast Sodium | Montelukast Sodium | 155 | 48 |
| Metformin Hcl | Metformin Hcl | 149 | 45 |
| Prednisone | Prednisone | 148 | 112 |
| Losartan Potassium | Losartan Potassium | 139 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 31 |
| Lovastatin | Lovastatin | 114 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 24 |
| Sertraline Hcl | Sertraline Hcl | 99 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 95 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 38 |
| Metformin Hcl Er | Metformin Hcl | 83 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 20 |
| Ozempic | Semaglutide | 76 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 24 |
| Ezetimibe | Ezetimibe | 72 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 24 |
| Tramadol Hcl | Tramadol Hcl | 71 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 66 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 17 |
| Meloxicam | Meloxicam | 64 | 17 |
| Bupropion Xl | Bupropion Hcl | 63 | 18 |
| Benazepril Hcl | Benazepril Hcl | 62 | 18 |
| Amoxicillin | Amoxicillin | 57 | 51 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 34 |
| Carvedilol | Carvedilol | 56 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 14 |
| Celecoxib | Celecoxib | 52 | 14 |
| Temazepam | Temazepam | 52 | suppressed |
| Allopurinol | Allopurinol | 51 | 17 |
| Synthroid | Levothyroxine Sodium | 50 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 31 |
| Furosemide | Furosemide | 46 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 12 |
| Estradiol | Estradiol | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 15 |
| Meclizine Hcl | Meclizine Hcl | 38 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Eliquis | Apixaban | 34 | 12 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 15 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | 11 |
| Ondansetron Odt | Ondansetron | 28 | 16 |
| Atenolol | Atenolol | 27 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 27 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 15 |
| Fluconazole | Fluconazole | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $60.33 · 4 records | Abbott Laboratories | AREXVY, BEXSERO, CAPVAXIVE, FREESTYLE LIBRE 3, GARDASIL 9, Heplisav-B, SHINGRIX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error